Navigation Links
Telik Announces Publication of Diabetes Research in Bioorganic & Medicinal Chemistry Letters

PALO ALTO, Calif., July 8 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK), today announced the publication of research in Bioorganic & Medicinal Chemistry Letters describing a novel class of small molecule compounds that could potentially lead to a new treatment for diabetes. These unique compounds are the result of an extensive medicinal chemistry effort at Telik to optimize the original lead structure identified through the application of Telik's TRAP(R) technology.

The compounds developed activate the insulin receptor and may have the potential to be an orally administered treatment for diabetes. Such small molecules have been actively sought after since the discovery of insulin in the 1920s by Banting and Best, and could represent a completely different approach to the treatment of Type 1 and Type 2 diabetes. Telik's publication, Robinson, L. et al., "5-Substituted isophthalamides as insulin receptor sensitizers," Bioorg. Med. Chem. Lett., 18: 3492 (2008), describes a series of compounds that are capable of activating the insulin receptor and were also shown to increase glucose transport into adipocytes.

"Telik's drug development focus does not include diabetes and other metabolic diseases," said Marc Steuer, Senior Vice President, Business Development. "It is our intention, therefore, to seek a licensee with the requisite development skills and expertise in this therapeutic area."

About Telik

Telik, Inc. of Palo Alto, CA, is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company's most advanced investigational drug candidates in clinical development are TELINTRA(R), a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA(R), a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP, which enables the rapid and efficient discovery of small molecule drug candidates. Additional information is available at

This press release contains "forward-looking" statements, including statements regarding the potential capabilities and qualities of the small molecules described above. These forward-looking statements are based upon Telik's current expectations. There are important factors that could cause Telik's results to differ materially from those indicated by these forward-looking statements. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in Telik's periodic filings with the Securities and Exchange Commission, including the factors described in the section entitled "Risk Factors" in its quarterly report on Form 10-Q for the quarter ended March 31, 2008. Telik does not undertake any obligation to update forward-looking statements contained in this press release.

TELIK, the Telik logo, TELINTRA, TELCYTA, and TRAP are trademarks or registered trademarks of Telik, Inc.

SOURCE Telik, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Telik Announces Presentation and Webcast at Needham Biotechnology Conference
2. Telik Announces First Quarter 2008 Financial Results
3. Telik Presents Preclinical Data at 99th Annual Meeting of the American Association for Cancer Research
4. Telik Announces Fourth Quarter and 2007 Year End Financial Results and 2008 Guidance
5. Telik Announces Revised Date for Year-End Financial Release, Conference Call and Webcast
6. Telik Announces Year-End Financial Release, Conference Call and Webcast
7. Telik Announces Presentation and Webcast at JPMorgan Healthcare Conference
8. Telik Announces Presentation and Webcast at UBS Global Life Sciences Conference
9. Telik Announces Presentation and Webcast at Bear Stearns Healthcare Conference
10. PAREXEL Announces Date of Fourth Quarter and Fiscal Year 2008 Earnings Release and Conference Call
11. Favrille Announces Resolution of Debt Obligations and Plans for Maximizing Assets
Post Your Comments:
(Date:11/30/2015)... 2015 Spherix Incorporated (Nasdaq: SPEX ... fostering and monetization of intellectual property, today provided ... designed to create shareholder value. ... "Based on published reports, the total addressable market ... and Spherix will seek to secure fair and ...
(Date:11/30/2015)... 30, 2015 Human Longevity, Inc. (HLI), the ... acquired Cypher Genomics, Inc., a leading genome informatics company ... software solutions. The San Diego -based ... Cypher CEO and Co-founder, Ashley Van Zeeland , Ph.D., ...  Financial details of the deal were not disclosed. ...
(Date:11/30/2015)... 2015  Aytu BioScience, Inc. (OTCQB: AYTU), a commercial-stage ... will present at two upcoming investor conferences. Aytu is ... virtual conference, to be held December 3, 2015, and ... held December 2 nd & 3 rd , ... streamed live via webcast. Josh Disbrow , ...
(Date:11/30/2015)... 30, 2015  Northwest Biotherapeutics (NASDAQ: NWBO ) ... immune therapies for solid tumor cancers, announced today that ... director, and the Company welcomes Neil Woodford,s ... recent anonymous internet report on NW Bio.  The Company,s ... Linda Powers stated, "We agree with Mr. Woodford ...
Breaking Biology Technology:
(Date:11/17/2015)... 2015  Vigilant Solutions announces today that Mr. ... Directors. --> --> ... the partnership at TPG Capital, one of the largest ... Billion in revenue.  He founded and led TPG,s Operating ... companies, from 1997 to 2013.  In his first role, ...
(Date:11/16/2015)... , Nov 16, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced expansion of its TDDI ... touch controller and display driver integration (TDDI) ... smartphones. These new TDDI products add to the ... resolution), TD4302 (WQHD resolution), and TD4322 (FHD resolution) ...
(Date:11/12/2015)... Nov. 12, 2015  Arxspan has entered into ... and Harvard for use of its ArxLab cloud-based ... tools. The partnership will support the institute,s efforts ... chemical research information internally and with external collaborators. ... for managing the Institute,s electronic laboratory notebook, compound ...
Breaking Biology News(10 mins):